CA
NZ
UK
US
AU
IND
Last update at 2025-06-18T17:04:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Wondering what's happening in today's after-hours session?
Mon 07 Apr 25, 11:00 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -40.57500M | -77.62300M | -32.56600M | -27.47500M | -20.53300M |
| Minority interest | - | - | - | - | - |
| Net income | -39.20800M | -67.63600M | -30.28000M | -29.86200M | -20.53300M |
| Selling general administrative | 10.79M | 14.47M | 14.94M | 12.40M | 7.42M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | - | - | - | 0.20M | 1.79M |
| Reconciled depreciation | 0.53M | 0.19M | 0.17M | 0.20M | 0.16M |
| Ebit | -41.33300M | -77.28000M | -30.31700M | -24.89300M | -15.77900M |
| Ebitda | -21.07800M | -32.48900M | -32.44100M | -23.09900M | -15.62000M |
| Depreciation and amortization | 20.25M | 44.79M | -2.12400M | 1.79M | 0.16M |
| Non operating income net other | - | - | -2.12400M | -2.08700M | - |
| Operating income | -41.33300M | -77.28000M | -30.31700M | -24.89300M | -16.19500M |
| Other operating expenses | 21.89M | 32.26M | 30.32M | 25.09M | 17.98M |
| Interest expense | 0.05M | 0.11M | 0.12M | 0.49M | 1.41M |
| Tax provision | -1.36700M | -9.98700M | - | - | - |
| Interest income | 0.11M | 0.09M | 0.12M | 0.15M | 0.01M |
| Net interest income | 0.06M | -0.02300M | -0.00300M | -0.34200M | -1.39400M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -1.36700M | -9.98700M | -2.28600M | 2.39M | -2.92900M |
| Total revenue | 0.00000M | 0.00000M | 0.00000M | 0.20M | 1.79M |
| Total operating expenses | 21.89M | 32.26M | 30.32M | 25.09M | 17.98M |
| Cost of revenue | - | - | - | - | 10.56M |
| Total other income expense net | 0.76M | -0.34300M | -2.24900M | -2.58200M | -2.94400M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -39.20800M | -67.63600M | -32.56600M | -27.47500M | -20.53300M |
| Net income applicable to common shares | - | -67.63600M | -32.56600M | -27.47500M | -34.75600M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 32.41M | 37.95M | 74.79M | 112.89M | 118.97M |
| Intangible assets | 25.25M | 25.25M | 32.07M | 77.09M | 77.09M |
| Earning assets | - | - | - | - | - |
| Other current assets | 1.06M | 1.21M | 1.14M | 1.19M | 1.28M |
| Total liab | 29.02M | 27.94M | 32.91M | 43.33M | 44.04M |
| Total stockholder equity | 3.39M | 10.01M | 41.88M | 69.55M | 74.94M |
| Deferred long term liab | - | - | - | 16.78M | 15.82M |
| Other current liab | 2.52M | 1.55M | 3.41M | 3.81M | 5.20M |
| Common stock | 0.00600M | - | 0.03M | 0.02M | 0.04M |
| Capital stock | 0.00600M | 0.00000M | 0.03M | 0.02M | 0.04M |
| Retained earnings | -844.82300M | -824.53200M | -785.32400M | -717.68800M | -685.12200M |
| Other liab | - | - | 10.91M | 19.58M | 15.82M |
| Good will | 0.00000M | 3.06M | 15.68M | 15.68M | 15.68M |
| Other assets | 0.00000M | - | 0.15M | 0.15M | 0.15M |
| Cash | 4.32M | 6.17M | 22.35M | 16.93M | 22.58M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 4.00M | 2.46M | 4.92M | 6.13M | 7.82M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | 12.51M | -3.89200M | -19.45500M | -13.14900M | -16.26500M |
| Short term debt | 0.67M | 0.66M | 0.82M | 1.16M | 0.91M |
| Short long term debt | 0.23M | 0.25M | 0.29M | 0.35M | 0.16M |
| Short long term debt total | 16.83M | 2.28M | 2.89M | 3.78M | 6.31M |
| Other stockholder equity | 848.21M | 834.54M | 827.18M | 787.22M | 760.02M |
| Property plant equipment | - | - | 3.39M | 1.84M | 0.80M |
| Total current assets | 5.38M | 7.38M | 23.49M | 18.12M | 23.86M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | -5.87100M | -23.22000M | -17.83700M |
| Short term investments | - | - | - | - | 0.00000M |
| Net receivables | - | - | - | - | - |
| Long term debt | - | - | - | 2.42M | 4.61M |
| Inventory | - | - | - | - | - |
| Accounts payable | 0.81M | 0.25M | 0.69M | 1.16M | 1.71M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 0.00000M | - | - | - | -6.37400M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 0.02M | 0.04M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | -717.68800M | -685.12200M |
| Treasury stock | - | - | - | -3.05400M | -3.05400M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.15M | 0.15M | 0.15M | 0.15M | 0.15M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 27.03M | 30.58M | 51.30M | 94.77M | 95.11M |
| Capital lease obligations | 1.60M | 2.03M | 2.60M | 1.01M | 1.54M |
| Long term debt total | - | - | - | 2.42M | 19.61M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 0.20M | -0.27900M | -0.29100M | 13.99M | -13.95900M |
| Change to liabilities | - | -0.46800M | -0.54700M | -5.65200M | 0.74M |
| Total cashflows from investing activities | - | -0.27900M | -0.29100M | 13.80M | -13.72700M |
| Net borrowings | - | -3.87200M | -3.22900M | -1.06300M | 6.00M |
| Total cash from financing activities | 3.08M | 29.36M | 19.96M | 21.77M | 38.74M |
| Change to operating activities | - | 0.41M | -0.78100M | -4.23700M | -0.46600M |
| Net income | -39.20800M | -67.63600M | -32.56600M | -27.47500M | -20.53300M |
| Change in cash | -16.17600M | 5.42M | -5.64800M | 11.37M | 9.32M |
| Begin period cash flow | 22.50M | 17.08M | 22.73M | 11.36M | 2.04M |
| End period cash flow | 6.33M | 22.50M | 17.08M | 22.73M | 11.36M |
| Total cash from operating activities | -19.45200M | -23.66400M | -25.31500M | -24.66300M | -15.78100M |
| Issuance of capital stock | 4.25M | 32.23M | 20.25M | 22.98M | 32.89M |
| Depreciation | 0.53M | 0.19M | 0.17M | 0.20M | 0.16M |
| Other cashflows from investing activities | - | - | - | 13.99M | 0.23M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | - | - | - | - | - |
| Sale purchase of stock | - | - | 20.39M | 22.98M | 32.89M |
| Other cashflows from financing activities | 0.20M | 1.00M | 3.49M | 0.85M | 7.50M |
| Change to netincome | - | 43.84M | 8.41M | 8.44M | 4.29M |
| Capital expenditures | 0.01M | 0.28M | 0.29M | 0.19M | 0.00900M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | -0.89300M | -0.33400M | -1.30100M |
| Exchange rate changes | - | - | - | 0.47M | 0.09M |
| Cash and cash equivalents changes | - | - | -5.64800M | 11.37M | 9.32M |
| Change in working capital | -1.77700M | -0.05800M | -1.32800M | -6.70500M | -0.56200M |
| Stock based compensation | 3.09M | 7.24M | 5.68M | 6.72M | 0.95M |
| Other non cash items | 19.28M | 46.59M | 1.59M | 0.88M | 0.86M |
| Free cash flow | -19.46500M | -23.94300M | -25.60600M | -24.85400M | -15.78100M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| WINT Windtree Therapeutics Inc |
-0.0255 4.27% | 0.57 | 0.29 | - | 660.53 | 0.53 | 706.08 | 0.05 |
| NVO Novo Nordisk A/S |
0.13 0.17% | 74.47 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-3.16 4.04% | 75.15 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
7.49 1.69% | 449.48 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
7.29 1.43% | 516.15 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.
2600 Kelly Road, Warrington, PA, United States, 18976-3622
| Name | Title | Year Born |
|---|---|---|
| Mr. Craig E. Fraser | Pres, CEO & Director | 1965 |
| Mr. John P. Hamill CPA | Sr. VP, CFO, Treasurer & Corp. Sec. | 1964 |
| Dr. Steven G. Simonson | Sr. VP & Chief Medical Officer | 1959 |
| Mr. Eric L. Curtis M.B.A. | Sr. VP & COO | 1969 |
| Mr. George Cox | VP of Technical Operations | 1952 |
| Ms. Diane Carman Esq. | Sr. VP & Gen. Counsel | 1969 |
| Dr. Pratap Paruchuru | Exec. Director of Clinical Devel. | NA |
| Ms. Tracy Rarick | Head of Operations & Program Management | NA |
| Dr. Ronald L. Dundore | Exec. Director of Regulatory Affairs & Quality | 1955 |
| Mr. Craig E. Fraser | Chairman, President, CEO & Interim Principal Officer | 1965 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...